10X Genomics Inc (OQ:TXG)

Apr 10, 2024 04:05 pm ET
10x Genomics to Report First Quarter 2024 Financial Results on April 30, 2024
PLEASANTON, Calif., April 10, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the first quarter ended March 31, 2024 after market close on Tuesday, April 30, 2024. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference
Mar 26, 2024 09:00 am ET
10x Genomics Commercially Launches Visium HD Spatial Gene Expression Assay
Began global shipments for Visium HD, a new product that enables whole transcriptome spatial discovery at single cell–scale resolution 
Mar 21, 2024 04:05 pm ET
10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel
Begins commercial shipments of Xenium Cell Segmentation Kit to improve determination of cell boundaries
Mar 14, 2024 01:49 pm ET
Johnson Fistel Announces Investigation of 10x Genomics (TXG) for Potential Securities Law Violations
Johnson Fistel, LLP is investigating 10x Genomics, Inc. (NASDAQ: TXG) (“10x Genomics” or the “Company”) for potential securities law violations. Shareholders who have incurred losses on their investment in the company are encouraged to contact the...
Feb 20, 2024 03:05 pm ET
10x Genomics to Present at the 44th Annual TD Cowen Health Care Conference
PLEASANTON, Calif., Feb. 20, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will participate in a fireside chat at the 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, at 2:50 p.m. Eastern Time.
Feb 15, 2024 03:05 pm ET
10x Genomics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Outlook for 2024
Q4 2023 revenue growth of 18% and FY 2023 revenue growth of 20% over the corresponding periods of 2022
Feb 07, 2024 03:05 pm ET
10x Genomics Expands Leadership in Single Cell Analysis with Launch of GEM-X Technology
GEM-X, the next generation of the company's leading single cell technology architecture, enables higher performance at larger scale and lower cost
Feb 05, 2024 03:05 pm ET
10x Genomics to Showcase New Cutting-Edge Technologies and Highlight Innovation Roadmap at 2024 AGBT General Meeting
New single cell and spatial products set to deliver higher performance, improve ease of use and enable researchers to measure more biology
Feb 01, 2024 06:52 am ET
TXG Alert: Johnson Fistel Announces Investigation of 10x Genomics for Potential Securities Law Violations
Johnson Fistel, LLP is investigating 10x Genomics, Inc. (NASDAQ: TXG) (“10x Genomics” or the “Company”) for potential securities law violations. Shareholders who have incurred losses on their investment in the Company are encouraged to contact the firm to learn about potentially recovering their losses. For more details on the investigation, visit:
Jan 30, 2024 10:05 am ET
Johnson Fistel Announces Investigation of 10x Genomics (TXG) for Potential Securities Law Violations
Johnson Fistel, LLP is investigating 10x Genomics, Inc. (NASDAQ: TXG) (“10x Genomics” or the “Company”) for potential securities law violations. Shareholders who have incurred losses on their investment in the company are encouraged to contact the...
Jan 24, 2024 03:05 pm ET
10x Genomics to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024
PLEASANTON, Calif., Jan. 24, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023 after market close on Thursday, February 15, 2024. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website pr
Jan 08, 2024 08:00 am ET
10x Genomics Announces Preliminary Fourth Quarter and Full Year 2023 Results
PLEASANTON, Calif., Jan. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary, unaudited select results for the fourth quarter and full year ended December 31, 2023.
Dec 21, 2023 03:05 pm ET
10x Genomics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PLEASANTON, Calif., Dec. 21, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 9:00 a.m. Pacific Time.
Dec 20, 2023 03:05 pm ET
10x Genomics Launches Xenium Catalyst Network
Founding Network Members Will Accelerate Access to Proof-of-Concept Data for Prospective Xenium Customers Worldwide
Dec 19, 2023 08:00 am ET
Integrative Study Conducted by 10x Genomics Combines Single Cell, Spatial and In Situ Analyses to Investigate Tumor Invasiveness
A team of 10x Genomics scientists conducted a comprehensive analysis of human breast tumor microenvironments using all three of its industry-leading platforms
Dec 13, 2023 03:26 pm ET
High Sensitivity and Specificity of the Xenium Platform from 10x Genomics Outperforms NanoString's CosMx and Vizgen's Merscope in Benchmarking Preprint
Xenium In Situ demonstrates higher transcript counts per gene in new comparison study of three spatial imaging platforms
Dec 07, 2023 08:00 am ET
10x Genomics and NIH CARD to Create Comprehensive Single Cell Atlas of the Human Brain
PLEASANTON, Calif., Dec. 7, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today a collaboration with the NIH Intramural Center for Alzheimer's and Related Dementias (NIH CARD) to build a more comprehensive single cell atlas of the human brain to further neuroscience research. Known for complementing a broad range of NIH-funded research that requires harnessing emerging technologies at scale, NIH CARD will use Chromium Single Cell Multiome to profile the epigenome and whole transcriptome across millions of individual cells from a
Nov 17, 2023 04:22 pm ET
10x Genomics Wins Another Patent Infringement Case Against NanoString Technologies
Jury Awards 10x Genomics Over $31 Million in Damages and Finds All Seven Asserted Patents Valid and Willfully Infringed by NanoString
Nov 06, 2023 03:05 pm ET
OWKIN Integrates 10x Genomics Spatial Omics and Single-Cell Technologies to the MOSAIC Study
PLEASANTON, Calif. and PARIS, Nov. 6, 2023 /PRNewswire/ -- OWKIN and 10x Genomics, Inc. (Nasdaq: TXG), announce they have entered into an agreement to add 10x Genomics spatial omics and single-cell technologies to the ambitious MOSAIC project, which has already garnered attention for its pioneering work in tumor analysis for therapeutic discovery.
Nov 02, 2023 04:05 pm ET
10x Genomics Reports Third Quarter 2023 Financial Results
PLEASANTON, Calif., Nov. 2, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2023.
Nov 01, 2023 04:05 pm ET
10x Genomics to Present at the Stephens 25th Annual Conference
PLEASANTON, Calif., Nov. 1, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will participate in a fireside chat at the Stephens 25th Annual Conference on Tuesday, November 14, at 10:00 a.m. Central Time.
Oct 26, 2023 04:05 pm ET
Study Fueled by Xenium Analysis Sheds Light on Resistance Mechanisms in Model of Lethal Pediatric Brain Tumors
Scientific pre-print featuring customer-generated data demonstrates the power of single cell spatial analysis to more directly assess unique tissue microenvironments and cell-cell interactions
Oct 11, 2023 04:05 pm ET
10x Genomics to Report Third Quarter 2023 Financial Results on November 2, 2023
PLEASANTON, Calif., Oct. 11, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today it will report financial results for the third quarter 2023 after market close on Thursday, November 2, 2023. The company will host a conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.
Oct 10, 2023 12:06 pm ET
10x Genomics Comments on Second UPC Preliminary Injunction Decision
UPC Denies Second Preliminary Injunction Request; Prior Injunctions Against NanoString's CosMx Products in Europe Remain in Full Effect
Sep 14, 2023 04:36 pm ET
10x Genomics Expands Gene Expression Flex Offering with New High-Throughput Multiomic Profiling Kit
Strengthen cellular analysis with cost-efficient multiomic readouts and streamlined workflows
Jul 13, 2023 04:05 pm ET
10x Genomics to Report Second Quarter 2023 Financial Results on August 3, 2023
PLEASANTON, Calif., July 13, 2023 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single cell and spatial biology, announced today it will report financial results for the second quarter 2023 after market close on Thursday, August 3, 2023. The company will host a conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.
Jul 05, 2023 07:30 pm ET
CAR T-Cell Study Enabled by 10x Genomics Single Cell Technology Published in Nature Medicine
Data Uncovers New Gene Signature to Help Understand Persistence in CAR T-cells
Jun 01, 2023 09:00 am ET
10x Genomics Files Two New Lawsuits Requesting Preliminary Injunctions Against NanoString's CosMx Products
Also Files New Suit Against Vizgen's MERSCOPE Products for Patent Infringement
May 24, 2023 04:05 pm ET
10x Genomics Launches Visium CytAssist Gene and Protein Expression Assay
Combining tissue profiling with whole transcriptome spatial analysis and high-plex protein co-detection enables a deeper, more holistic understanding of tissue organization
May 17, 2023 04:05 pm ET
10x Genomics Wins Permanent Injunction Against NanoString's CosMx Products
10x Genomics is seeking additional injunctions to protect its intellectual property
May 03, 2023 04:05 pm ET
10x Genomics Reports First Quarter 2023 Financial Results
PLEASANTON, Calif., May 3, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the first quarter ended March 31, 2023.
Apr 25, 2023 04:06 pm ET
10x Genomics to Present at the BofA Securities 2023 Healthcare Conference
PLEASANTON, Calif., April 25, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced that members of its management team will participate in a fireside chat at the BofA Securities 2023 Healthcare Conference on Wednesday, May 10, at 2:20 p.m. Pacific Time.
Apr 12, 2023 04:05 pm ET
10x Genomics to Report First Quarter 2023 Financial Results on May 3, 2023
PLEASANTON, Calif., April 12, 2023 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced it will report financial results for the first quarter 2023 after market close on Wednesday, May 3, 2023. The company will host a conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.  The news release with the financial results will be accessible from the company's website prior to the conference c
Feb 06, 2023 08:00 am ET
10x Genomics Demonstrates Breadth, Scale and Leadership at 2023 AGBT General Meeting
Showcases unique power and scalability of Chromium Flex across fresh, frozen and FFPE samples, including data from an 8 million cell experiment on a single runReinforces performance advantages of Visium CytAssist for unbiased spatial discovery with new data and an exclusive product pipeline, including Visium HDShares technology roadmap for the Xenium platform, including a broader menu of targeted and customizable panels and the future capability to scale to thousands of plexLaunches Xenium Catalyst Program to accelerate researchers' access to high-quality, proof-of-concept in situ dataPLEASA
Jan 19, 2023 03:05 pm ET
10x Genomics to Report Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023
PLEASANTON, Calif., Jan. 19, 2023 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the fourth quarter and full year ended December 31, 2022 after market close on Wednesday, February 15, 2023. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.
Dec 28, 2022 03:05 pm ET
10x Genomics to Present at the 41st Annual J.P. Morgan Healthcare Conference
PLEASANTON, Calif., Dec. 28, 2022  /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the company will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California.
Dec 08, 2022 03:05 pm ET
10x Genomics Commercially Launches Xenium Platform for In Situ Analysis
Began global shipments of Xenium Analyzer, the highest throughput instrument for subcellular In Situ profiling
Nov 09, 2022 03:05 pm ET
10x Genomics Launches BEAM to Improve and Streamline Antibody and T-Cell Receptor Discovery
Barcode Enabled Antigen Mapping (BEAM) screens multiple antigens against thousands of B- or T-cells to identify novel and rare antigen-specific repertoires
Nov 02, 2022 04:05 pm ET
10x Genomics Reports Third Quarter 2022 Financial Results
PLEASANTON, Calif., Nov. 2, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the third quarter ended September 30, 2022.
Oct 31, 2022 04:05 pm ET
10x Genomics to Host Investor Day on December 8, 2022
PLEASANTON, Calif., Oct. 31, 2022 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG) today announced it will host an Investor Day on December 8, 2022 at the company's headquarters in Pleasanton, CA starting at 9:00 a.m. Pacific Time. The event will feature presentations by several members of the company's leadership team and will include Q&A discussion between the audience and 10x Genomics panel members.
Oct 12, 2022 04:05 pm ET
10x Genomics to Report Third Quarter Financial Results on November 2, 2022
PLEASANTON, Calif., Oct. 12, 2022 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the third quarter 2022 after market close on Wednesday, November 2, 2022. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.
Sep 02, 2022 04:05 pm ET
10x Genomics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
PLEASANTON, Calif., Sept. 2, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the company will be participating in the upcoming Morgan Stanley 20th Annual Global Healthcare Conference in New York, New York.
Aug 08, 2022 04:05 pm ET
10x Genomics Reports Second Quarter 2022 Financial Results
PLEASANTON, Calif., Aug. 8, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the second quarter ended June 30, 2022.
Jul 28, 2022 04:05 pm ET
10x Genomics to Present at the UBS Genomics 2.0 and MedTech Innovations Summit
PLEASANTON, Calif. , July 28, 2022 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the company will be participating in the upcoming UBS Genomics 2.0 and MedTech Innovations Summit in Dana Point, California.
Jul 14, 2022 04:06 pm ET
10x Genomics Names Jim Wilbur as Chief Commercial Officer
PLEASANTON, Calif., July 14, 2022 /PRNewswire/ -- Following a comprehensive search process, 10x Genomics, Inc. (Nasdaq: TXG), today announced the hiring of Jim Wilbur, Ph.D., as Chief Commercial Officer, effective July 27. In this role, Wilbur will be responsible for driving commercial strategy and execution and leading the company's sales, support and marketing functions.
Jul 14, 2022 04:05 pm ET
10x Genomics Announces Preliminary Second Quarter 2022 Revenue
PLEASANTON, Calif., July 14, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced that its preliminary revenue is expected to be approximately $114.5 million for the second quarter ended June 30, 2022. This represents an approximate 1% decrease from $115.8 million for the prior year period, and flat revenue sequentially.
Jun 07, 2022 07:00 am ET
10x Genomics Advances Leadership and Innovation in Single Cell and Spatial Technologies at 2022 AGBT General Meeting
Demonstrates first-ever commercial product capable of single-cell RNA sequencing on FFPE tissuesOpens preorders for CytAssist, the company's first spatial instrument Shares new data on the company's Xenium In Situ Analyzer, expected to ship by year-endPLEASANTON, Calif., June 7, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced a series of product updates that will be presented at the 2022 Advances in Genome Biology and Technology (AGBT) General Meeting this week in Orlando, Fla. The latest deve
May 04, 2022 04:05 pm ET
10x Genomics Reports First Quarter 2022 Financial Results
Q1 2022 revenue growth of 8% over prior year
Apr 26, 2022 04:05 pm ET
10x Genomics to Present at the BofA Securities 2022 Healthcare Conference
PLEASANTON, Calif., April 26, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the company will be participating in the upcoming BofA Securities 2022 Healthcare Conference in Las Vegas, Nevada.
Apr 14, 2022 08:55 am ET
10x Genomics Launches Two New Products to Unlock Wider Range of Samples for Single Cell Analysis on Chromium
Fixed RNA Profiling Kit stabilizes human samples at collection; Nuclei Isolation Kit simplifies frozen sample analysis
Apr 07, 2022 04:05 pm ET
10x Genomics to Report First Quarter Financial Results on May 4, 2022
PLEASANTON, Calif., April 7, 2022 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the first quarter 2022 after market close on Wednesday, May 4, 2022. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.
Mar 01, 2022 03:05 pm ET
10x Genomics to Present at the Cowen 42nd Annual Health Care Conference
PLEASANTON, Calif., March 1, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the company will be participating in the upcoming Cowen 42nd Annual Health Care Conference.
Feb 22, 2022 03:15 pm ET
10x Genomics Showcases Robust Innovation Pipeline at Xperience 2022 Event
PLEASANTON, Calif,, Feb. 22, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today unveiled new details about upcoming products and capabilities across its single cell, spatial, and in situ platforms at its second annual Xperience 2022 virtual event. Highlights included the Fixed RNA Profiling Kit, which improves sample preparation workflow and adds flexibility for Chromium single cell experiments; Visium CytAssist, to expand the number of tissue samples accessible to the spatial platform; and the first-ever
Feb 16, 2022 03:05 pm ET
10x Genomics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Outlook for 2022
PLEASANTON, Calif., Feb. 16, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided outlook for 2022.
Jan 26, 2022 03:05 pm ET
10x Genomics to Report Fourth Quarter and Full Year 2021 Financial Results on February 16, 2022
PLEASANTON, Calif., Jan. 26, 2022 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the fourth quarter and full year ended December 31, 2021 after market close on Wednesday, February 16, 2022. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.
Jan 21, 2022 08:00 am ET
10x Genomics Adds Global Clinical Research Organizations to Expanded Certified Service Provider Network
PLEASANTON, Calif., Jan. 21, 2022 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the expansion of its 10x Certified Service Provider (CSP) Network to include three leading clinical research organizations (CROs). The organizations will partner with 10x Genomics to support global biopharmaceutical companies seeking to leverage 10x Genomics' robust single-cell and spatial technologies to power new therapeutic discoveries and accelerate drug development. The three organizations selected for the 10x Genomics
Dec 22, 2021 03:05 pm ET
10x Genomics to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference
PLEASANTON, Calif., Dec. 22, 2021 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG) today announced the company will be participating in the upcoming 40th Annual J.P. Morgan Healthcare Conference.
Dec 01, 2021 04:06 pm ET
10x Genomics Recognized on The Scientist's Top 10 Innovations List for Fifth Consecutive Year
PLEASANTON, Calif., Dec. 1, 2021 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced that Chromium X has been named one of The Scientist's 2021 Top 10 Innovations, an annual list of newly released products that have the potential to generate the biggest impact on scientific research. This recognition marks the fifth consecutive year that a 10x Genomics product made the list, with a total of seven products appearing as Top 10 Innovations since 2015.
Nov 03, 2021 04:05 pm ET
10x Genomics Reports Third Quarter 2021 Financial Results
PLEASANTON, Calif., Nov. 3, 2021 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the third quarter ended September 30, 2021.
Oct 25, 2021 06:00 am ET
10x Genomics Celebrates Opening of Singapore Manufacturing and Commercial Hub
SINGAPORE, Oct. 25, 2021 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today marked a major Asia Pacific (APAC) expansion with the grand opening celebration of its Singapore manufacturing facility and commercial hub.
Oct 07, 2021 04:05 pm ET
10x Genomics to Report Third Quarter Financial Results on November 3, 2021
PLEASANTON, Calif., Oct. 7, 2021 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the third quarter 2021 after market close on Wednesday, November 3rd, 2021. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.
Aug 31, 2021 04:05 pm ET
10x Genomics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the Morgan Stanley 19th Annual Global Healthcare Conference. 10x Genomics’ management is scheduled to present on Monday, September 13th, at 2:45 p.m. Eastern...
Aug 06, 2021 08:00 am ET
10x Genomics to Present at the UBS Genomics 2.0 and MedTech Innovations Summit
10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the upcoming UBS Genomics 2.0 and MedTech Innovations Summit. 10x Genomics’ management is scheduled to present on Tuesday, August 10th at 6:00 p.m. Eastern...
Aug 04, 2021 04:05 pm ET
10x Genomics Reports Second Quarter 2021 Financial Results
10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the second quarter ended June 30, 2021. Recent Highlights Revenue was $115.8 million for the second quarter, representing a 170% increase over the corresponding period of 2020...
Jul 27, 2021 06:30 am ET
10x Genomics Signs Global Patent Cross License Agreement with Bio-Rad
10x Genomics, Inc. (Nasdaq: TXG) today announced that it has entered into a global settlement and cross-license agreement with Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb). The agreement resolves all outstanding litigation and other proceedings...
Jul 14, 2021 08:00 am ET
10x Genomics Introduces New Chromium X Series for Single Cell Analysis
Building on its industry leading position in single cell analysis, 10x Genomics (NASDAQ: TXG) today announced commercial availability of its new Chromium X Series, a next-generation platform for single cell analysis. The new Series comprises the...
Jul 07, 2021 04:03 pm ET
10x Genomics to Report Second Quarter Financial Results on August 4, 2021
10x Genomics (Nasdaq: TXG) today announced it will report financial results for the second quarter 2021 after market close on Wednesday, August 4th, 2021. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m....
Jun 10, 2021 08:00 am ET
10x Genomics Unlocks Whole Transcriptome Analysis in FFPE Tissues With New Visium Assay, Now Shipping
10x Genomics, Inc. (Nasdaq: TXG) today announced it is shipping its new Visium Spatial Gene Expression for FFPE (formalin-fixed and paraffin-embedded) assay. The offering gives researchers access to the whole transcriptome across their entire...
May 24, 2021 08:00 am ET
10x Genomics to Participate in Upcoming June Investor Conferences
10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating virtually in the following investor conferences: William Blair 41st Annual Growth Stock ConferenceFireside Chat on Wednesday, June 2nd at 2:20 p.m. Eastern...
May 05, 2021 04:03 pm ET
10x Genomics Reports First Quarter 2021 Financial Results
10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the first quarter ended March 31, 2021. Recent Highlights Revenue was $105.8 million for the first quarter, representing a 47% increase over the corresponding period of...
Apr 29, 2021 04:05 pm ET
10x Genomics to Present at the BofA Securities 2021 Virtual Healthcare Conference
10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the upcoming BofA Securities 2021 Virtual Healthcare Conference. 10x Genomics’ management is scheduled to present on Wednesday, May 12th at 3:30 p.m. Eastern...
Apr 08, 2021 04:05 pm ET
10x Genomics to Report First Quarter Financial Results on May 5, 2021
10x Genomics (Nasdaq: TXG) today announced it will report financial results for the first quarter 2021 after market close on Wednesday, May 5th, 2021. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m....
Apr 01, 2021 08:30 am ET
10x Genomics Puts Single Cell Analysis Within Reach of All With Low Throughput Gene Expression Kit
10x Genomics, Inc. (Nasdaq: TXG) today announced the launch of its Chromium Single Cell Gene Expression Low Throughput (LT) Kit, a new offering designed to put the power of single cell analysis within the reach of more scientists than ever before....
Mar 09, 2021 08:30 am ET
10x Genomics Expands Pleasanton Headquarters with New Facilities at Two Locations
10x Genomics, Inc. (Nasdaq: TXG) today announced expansion plans to support the company’s continued growth in Pleasanton across two properties. Along with the leasing of a second building in the same complex as its current headquarters, 10x has...
Feb 25, 2021 08:05 am ET
10x Genomics to Present at the 41st Annual Cowen Health Care Conference
10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the upcoming 41st Annual Cowen Health Care Conference. 10x Genomics’ management is scheduled to present on Wednesday, March 3 at 2 p.m. Eastern Time. Interested...
Feb 24, 2021 04:05 pm ET
10x Genomics Showcases Next Wave of Innovations at First Ever Xperience Event
10x Genomics, Inc. (Nasdaq: TXG) today detailed a slew of new products and announced the acquisition of Copenhagen-based Tetramer Shop at its inaugural Xperience 2021 event, a showcase with three breakout sessions corresponding to 10x’s three...
Feb 17, 2021 04:03 pm ET
10x Genomics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Outlook for 2021
10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the fourth quarter and full year ended December 31, 2020 and provides outlook for full year 2021. Recent Highlights Revenue was $298.8 million for the full year and $112.2...
Jan 28, 2021 04:09 pm ET
10x Genomics to Report Fourth Quarter and Full Year 2020 Financial Results on February 17, 2021
10x Genomics (Nasdaq: TXG) today announced it will report financial results for the fourth quarter and full year ended December 31, 2020 after market close on Wednesday, February 17, 2021. The company’s management will webcast a corresponding...
Dec 23, 2020 04:03 pm ET
10x Genomics to Present at the 39th Annual J.P. Morgan Healthcare Conference
10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming 39th Annual J.P. Morgan Virtual Healthcare Conference. 10x Genomics’ management is scheduled to present on Monday, January 11 at 7:00 a.m. Pacific Time /...
Nov 10, 2020 04:05 pm ET
10x Genomics Reports Third Quarter 2020 Financial Results
10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the third quarter ended September 30, 2020. Recent Highlights Revenue was $71.8 million for the third quarter, representing a 17% increase over the corresponding period in...
Nov 04, 2020 06:00 pm ET
10x Genomics to Participate in the Stifel 2020 Healthcare Conference
10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming Stifel Virtual Healthcare Conference. 10x Genomics’ management is scheduled to present on Monday, November 16 at 11:40 a.m. Pacific Time / 2:40 p.m....
Oct 13, 2020 04:15 pm ET
10x Genomics to Report Third Quarter Financial Results on November 10, 2020
10x Genomics (Nasdaq: TXG) today announced it will report financial results for the third quarter 2020 after market close on Tuesday, November 10, 2020. The company’s management will webcast a corresponding conference call beginning at 2:00 p.m....
Oct 05, 2020 04:15 pm ET
10x Genomics Advances into Emerging Field of In Situ Analysis with Two Acquisitions
Continuing on its mission of mastering biology to advance human health, 10x Genomics, Inc. (Nasdaq: TXG) today announced that it has entered into a definitive agreement to acquire ReadCoor, Inc., developer of foundational In Situ technologies,...
Sep 15, 2020 04:25 pm ET
10x Genomics Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
10x Genomics, Inc. (NASDAQ: TXG) (the “Company”) today announced the closing of its public offering of 4,600,000 shares of its Class A common stock, which included the exercise in full of the underwriters’ option to purchase 600,000 additional...
Sep 15, 2020 08:00 am ET
10x Genomics First to Market With Product to Simultaneously Capture Epigenome and Transcriptome
10x Genomics (Nasdaq: TXG) today announced it has begun shipping its Chromium Single Cell Multiome ATAC + Gene Expression solution to customers, marking the first commercial release of a product capable of simultaneously profiling the epigenome and...
Sep 10, 2020 11:16 pm ET
10x Genomics Announces Pricing of Upsized Public Offering
10x Genomics, Inc. (NASDAQ: TXG) (the “Company”) today announced the pricing of an upsized underwritten public offering by the Company of its Class A common stock at a price to the public of $110.00 per share, before underwriting discounts and...
Sep 08, 2020 04:21 pm ET
10x Genomics Announces Launch of a Follow-On Public Offering
10x Genomics, Inc. (NASDAQ: TXG) (the “Company”) today announced that the Company has commenced an underwritten public offering of 3,500,000 shares of the Company’s Class A common stock to be issued by the Company pursuant to a registration...
Sep 01, 2020 04:03 pm ET
10x Genomics to Participate in the Morgan Stanley 2020 Healthcare Conference
10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming Morgan Stanley Virtual Healthcare Conference. 10x Genomics’ management is scheduled to participate in a fireside chat on Wednesday, September 16 at 8:45...
Aug 11, 2020 04:05 pm ET
10x Genomics Reports Second Quarter 2020 Financial Results
10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the second quarter ended June 30, 2020. Recent Highlights Revenue was $42.9 million for the second quarter, representing a 23% decrease over the corresponding period in 2019,...
Aug 06, 2020 05:00 pm ET
10x Genomics to Participate in the UBS Genomics 2.0 and Medtech Innovations Summit
10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming UBS Genomics 2.0 and Medtech Innovations Virtual Summit. 10x Genomics’ management is scheduled to participate in a fireside chat on Wednesday, August 12...
Jul 14, 2020 09:00 am ET
10x Genomics Launches Next Generation Immune Profiling Product to Combat COVID-19
10x Genomics (Nasdaq: TXG) strengthened the research toolkit of scientists around the globe today with the launch of its Chromium Single Cell Immune Profiling v2 product. The new product extends the capabilities of the original version, supporting...
Jul 08, 2020 05:43 pm ET
10x Genomics to Report Second Quarter Financial Results on August 11, 2020
10x Genomics (Nasdaq: TXG) today announced it will report financial results for the second quarter 2020 after market close on Tuesday, August 11, 2020. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m....
Jun 17, 2020 09:00 am ET
10x Genomics Selects First 45 Members for Visium Clinical Translational Research Network
10x Genomics, Inc. (Nasdaq: TXG) today unveiled the first 45 members selected for participation in its Visium Clinical Translational Research Network (CTRN). Members selected are focused on research in oncology, immuno-oncology, neuroscience,...
May 20, 2020 09:00 am ET
Focusing on the Genes that Matter Most: 10x Genomics Launches Targeted Gene Expression Solution
Building on its earlier reveal at the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG) today launched its Targeted Gene Expression Solution for single cell and shortly following for spatial genomic...
May 19, 2020 09:15 am ET
10x Genomics Becomes First One Medical Customer to Deploy Cohort-Based COVID-19 Employee Testing
Today, 10x Genomics (Nasdaq: TXG) and One Medical (Nasdaq: ONEM) announced the two organizations are partnering to pioneer a path toward the safe return to work by deploying a comprehensive approach to COVID-19 testing, digital employee symptom...
May 19, 2020 09:00 am ET
10x Genomics Becomes First One Medical Customer to Deploy Cohort-Based COVID-19 Employee Testing 
Today, 10x Genomics (Nasdaq: TXG) and One Medical (Nasdaq: ONEM) announced the two organizations are partnering to pioneer a path toward the safe return to work by deploying a comprehensive approach to COVID-19 testing, digital employee symptom...
May 11, 2020 04:03 pm ET
10x Genomics Reports First Quarter 2020 Financial Results
10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the quarter ended March 31, 2020. Recent Highlights Revenue of $71.9 million for the first quarter, representing a 34% increase over the corresponding period of 2019 Announced...
May 05, 2020 04:03 pm ET
10x Genomics to Present at the BofA Securities 2020 Healthcare Conference
10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming BofA Securities Virtual Healthcare Conference. 10x Genomics’ management is scheduled to present on Wednesday, May 13 at 8:00 a.m. Pacific Time / 11:00...
Apr 24, 2020 08:00 am ET
10x Genomics to Report First Quarter Financial Results on May 11, 2020
10x Genomics (Nasdaq: TXG) today announced it will report financial results for the first quarter 2020 after market close on Monday, May 11, 2020. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific...
Apr 09, 2020 04:03 pm ET
10x Genomics Provides COVID-19 Business Impact Update and Response
10x Genomics (Nasdaq: TXG), today provided an update on the actions it is taking to focus its business operations to support critical research in response to the coronavirus (COVID-19) pandemic as well as the financial impact. Supporting COVID-19...
Apr 02, 2020 09:00 am ET
10x Genomics Appoints Kim Popovits to Board of Directors
10x Genomics, Inc. (Nasdaq: TXG) today announced the appointment of Kim Popovits, former Chairman of the Board, President and Chief Executive Officer of Genomic Health, Inc., to the company’s Board of Directors.  She brings decades of experience in...
Feb 25, 2020 08:00 am ET
10x Genomics to Present at the 40th Annual Cowen Health Care Conference
10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the upcoming 40th Annual Cowen Health Care Conference in Boston, MA. 10x Genomics’ management is scheduled to present on Tuesday, March 3 at 10:40 a.m....
Feb 24, 2020 12:00 pm ET
10x Genomics Debuts Range of New Products at AGBT
10x Genomics, Inc. (Nasdaq: TXG) today announced a broad range of new products at the Advances in Genome Biology and Technology (AGBT) General Meeting, as well as new capabilities for existing products. Today’s announcements further 10x Genomics’...
Feb 18, 2020 04:01 pm ET
10x Genomics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Full Year 2020 Revenue Guidance
10x Genomics, Inc. (Nasdaq: TXG), today reported financial results for the fourth quarter and full year ended December 31, 2019. Recent Highlights Revenue of $75.3 million for the fourth quarter and $245.9 million for the full year of 2019,...
Feb 04, 2020 04:05 pm ET
10x Genomics to Report Fourth Quarter and Full Year 2019 Financial Results on February 18, 2020
10x Genomics (Nasdaq: TXG) today announced it will report financial results for the fourth quarter and full year ended December 31, 2019 after market close on Tuesday, February 18, 2020. Company management will host a corresponding conference call...
Jan 07, 2020 04:05 pm ET
10x Genomics to Present at the 38th Annual J.P. Morgan Healthcare Conference
10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the upcoming 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. 10x Genomics’ management is scheduled to present on Tuesday, January 14 at...
Nov 26, 2019 09:00 am ET
10x Genomics Begins Shipments of Visium Spatial Gene Expression Solution
10x Genomics (Nasdaq: TXG) today announced it has begun shipping its Visium Spatial Gene Expression Solution. The Visium Spatial Gene Expression Solution is the first new product to result from 10x Genomics’ acquisition of Sweden’s Spatial...
Nov 07, 2019 04:03 pm ET
10x Genomics Reports Third Quarter 2019 Financial Results and Provides 2019 Revenue Guidance
10x Genomics, Inc. (Nasdaq: TXG), today reported financial results for the third quarter ended September 30, 2019. Recent Highlights Revenue of $61.2 million for the third quarter of 2019, representing a 67% increase over the third quarter of...
Oct 25, 2019 04:45 pm ET
10x Genomics to Report Third Quarter 2019 Financial Results on November 7, 2019
10x Genomics (Nasdaq: TXG) today announced it will report financial results for the third quarter 2019 after market close on Thursday, November 7, 2019. Company management will host a corresponding conference call beginning at 2:00 p.m. Pacific...
Sep 16, 2019 04:10 pm ET
10x Genomics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
10x Genomics (Nasdaq: TXG) today announced the closing of its initial public offering of 11,500,000 shares of its Class A common stock, which includes the exercise in full of the underwriters’ option to purchase 1,500,000 additional shares of its...
Sep 12, 2019 07:00 am ET
10x Genomics Announces Pricing of Initial Public Offering
10x Genomics, Inc. (“10x Genomics”) today announced the pricing of its initial public offering of its Class A common stock at a price of $39.00 per share, before underwriting discounts and commissions. 10x Genomics is offering 10,000,000 shares of...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.